Anti-BTK (phospho Y223) antibody [EP420Y] (ab68217)

Publishing research using ab68217? Please let us know so that we can cite the reference in this datasheet.

ab68217 has been referenced in 5 publications.

  • Guo W  et al. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis 5:e1409 (2014). PubMed: 25188519
  • Dong S  et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 124:3583-6 (2014). WB ; Human . PubMed: 25258342
  • Yang G  et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 122:1222-32 (2013). PubMed: 23836557
  • Evans EK  et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 346:219-28 (2013). WB ; Human . PubMed: 23709115
  • Liao C  et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res Ther 15:R146 (2013). WB ; Human . PubMed: 24286216

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"